Xilio Therapeutics earnings were -$56.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest XLO earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$15.8M, up 19.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, XLO reported annual earnings of -$58.2M, with -23.8% growth.
What were Xilio Therapeutics's earnings last quarter?
On XLO's earnings call on Invalid Date, Xilio Therapeutics (NASDAQ: XLO) reported Q2 2025 earnings per share (EPS) of -$0.16, up 33.33% year over year. Total XLO earnings for the quarter were -$15.84 million. In the same quarter last year, Xilio Therapeutics's earnings per share (EPS) was -$0.24.
As of the last Xilio Therapeutics earnings report, Xilio Therapeutics is currently losing money. Xilio Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$56.22 million, a 14.21% decrease year over year.
What was XLO's earnings growth in the past year?
As of Xilio Therapeutics's earnings date in Invalid Date, Xilio Therapeutics's earnings has grown year over year. XLO earnings in the past year totalled -$56.22 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.